secwatch.observer — SEC 8-K summary
======================================

Issuer:     Praxis Precision Medicines, Inc. (PRAX)
CIK:        0001689548
Form:       8-K
Filed at:   2026-08-06T12:31:27+00:00
Accession:  0001689548-26-000082
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Praxis Q2 net loss $83.7M; FDA mid-cycle positive for ulixacaltamide and relutrigine; no AdCom
--------------------------------------------------------------------------------

- FDA mid-cycle meetings for ulixacaltamide (ET) and relutrigine (DEEs) found no major safety/efficacy concerns; no advisory committee planned; PDUFA dates Jan 29, 2027 and Dec 27, 2026.
- BIMO inspections for both NDAs completed with no Form 483 observations.
- Third Breakthrough Therapy Designation granted for elsunersen in SCN2A DEE (gain-of-function).
- Q2 2026 net loss $83.7M; cash $1.4B, runway into 2028.
- Vormatrigine POWER1 missed primary endpoint but met secondary; plans to restart POWER2 and start POWER3 in Q4 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1689548/000168954826000082/0001689548-26-000082-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1689548/000168954826000082/prax-20260806.htm
  HTML page:      https://secwatch.observer/filing/0001689548-26-000082

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer